Abbott’s new pharma spinout takes in-house execs with it
Abbott (NYSE:ABT) unveiled an executive roster for its AbbVie pharmaceutical spinout that pulls leadership from within the Abbott family.
Current pharmaceutical chief Richard Gonazalez will become chairman and CEO for AbbVie, to be joined by licensing and acquisitions vice president William Chase as CFO and compensation & benefits senior VP Timothy Richmond as chief human resources officer.
Abbot general counsel Laura Schumacher, pharma R&D VP John Leonard and proprietary pharma product VP Carlos Alban will all retain their roles when switching to AbbVie.
Read more
Post-bankruptcy HemCon names Barry Starkman CEO
Portland, Ore.-based HemCon Medical Technologies named former Promega operations vice president Barry Starkman CEO following its decision to file for Chapter 11 bankruptcy after losing a $34.2 million court verdict to Marine Polymer Technologies.
Read more
Digirad appoints John Climaco to board
Digirad Corp. (NSDQ:DRAD) appointed Axial Biotech president & CEO to its board of directors, effective immediately.
Read more
